Stock REVB REVELATION BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.18 USD +1.87% Intraday chart for Revelation Biosciences, Inc. -2.68% -85.49%
Mar. 22 Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Mar. 22 Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).

Number of employees: 9

Managers

Managers TitleAgeSince
James Rolke CEO
 Chief Executive Officer 55 20-04-30
Chester Zygmont DFI
 Director of Finance/CFO 44 20-04-30
Sandra Vedrick IRC
 Investor Relations Contact - -
Robin Marsden PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
George Tidmarsh CHM
 Chairman 64 20-04-30
Jess Roper BRD
 Director/Board Member 59 20-09-30
James Rolke CEO
 Chief Executive Officer 55 20-04-30
Lakhmir Chawla BRD
 Director/Board Member 53 23-09-26
Jennifer Carver BRD
 Director/Board Member 70 20-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,632,935 1,627,645 ( 99.68 %) 0 99.68 %

Shareholders

NameEquities%Valuation
Walleye Capital LLC
0.8437 %
13,777 0.8437 % 37 749 $
Sabby Management LLC
0.8231 %
13,441 0.8231 % 36 828 $
AXA Investment Managers UK Ltd.
0.1143 %
1,866 0.1143 % 5 113 $
George Tidmarsh
0.0860 %
1,404 0.0860 % 3 847 $
Geode Capital Management LLC
0.0729 %
1,190 0.0729 % 3 261 $
James Rolke
0.0415 %
678 0.0415 % 1 858 $
Chester Zygmont
0.0405 %
661 0.0405 % 1 811 $
Jennifer Carver
0.006491 %
106 0.006491 % 290 $
Tower Research Capital LLC
0.004654 %
76 0.004654 % 208 $
Intracoastal Capital LLC
0.004287 %
70 0.004287 % 192 $
NameEquities%Valuation
Linden Advisors LP
-
715,752 - 18 610 $
Pine Valley Investments LLC
-
291,145 - 7 570 $
Yakira Capital Management, Inc.
-
246,884 - 6 419 $
Walleye Capital LLC
-
187,001 - 4 862 $
Telemetry Investments LLC
-
143,115 - 3 721 $
Walleye Trading LLC
-
104,990 - 2 730 $
Cowen & Co. LLC
-
100,100 - 2 603 $
Ayrton Capital LLC
-
75,000 - 1 950 $
Wolverine Asset Management LLC
-
72,202 - 1 877 $
Jane Street Group LLC
-
50,000 - 1 300 $

Company contact information

Revelation Biosciences, Inc.

4660 LaJolla Village Drive Suite 100

92122, San Diego

+650 800 3717

http://www.revbiosciences.com
address Revelation Biosciences, Inc.(REVB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.18 USD
Average target price
32.12 USD
Spread / Average Target
+1,373.62%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
REVELATION BIOSCIENCES, INC. Stock Revelation Biosciences, Inc.
-85.49% 3.56M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. REVB Stock
  4. Company Revelation Biosciences, Inc.